Introduction
B31 is a well‑studied bacteriophage that infects members of the genus Bacillus, particularly Bacillus subtilis. The phage was first isolated in the 1960s from soil samples in the United States and has since been used extensively in molecular genetics, microbiology, and phage therapy research. B31 is a member of the order Caudovirales and the family Siphoviridae, characterized by a long, non‑contractile tail and a icosahedral capsid. Its relatively small genome, simple structure, and well‑defined host range make it an ideal model system for studies of phage biology, host‑pathogen interactions, and biotechnological applications.
Taxonomy and Nomenclature
The International Committee on Taxonomy of Viruses (ICTV) classifies B31 in the following hierarchy:
- Order: Caudovirales
- Family: Siphoviridae
- Genus: PhageB (proposed)
- Species: B31
Within Siphoviridae, B31 shares phylogenetic similarities with the well‑characterized phages such as P1 and P2, but possesses unique genes that confer distinct lytic properties and host specificity.
Historical Naming Conventions
The designation “B31” originates from a series of phage isolates collected in the 1960s, where phages were labeled sequentially with letters indicating the bacterial host and numbers indicating the order of isolation. The “B” refers to the Bacillus host, while “31” denotes the 31st phage isolated from the sample set.
Morphology and Structural Features
B31 exhibits the classic morphology of Siphoviridae phages. The virion consists of an icosahedral capsid approximately 55 nm in diameter, surrounded by a long, flexible tail of about 150 nm. The tail is composed of a central tube and peripheral fibers that facilitate attachment to bacterial cell surfaces.
Capsid Architecture
The capsid of B31 is constructed from 12 identical capsid proteins, each forming a pentameric or hexameric subunit. Cryo-electron microscopy studies have revealed a T=7 icosahedral lattice, typical of many tailed phages. The capsid proteins exhibit high structural conservation with other Siphoviridae members, indicating a shared evolutionary origin.
Tail Structure
Unlike contractile-tailed phages, B31’s tail remains extended during infection. The tail fibers contain receptor-binding domains that recognize specific teichoic acid components on the surface of Bacillus subtilis. This interaction is a critical determinant of host specificity and infection efficiency.
Genomic Characteristics
The genome of B31 is a linear, double-stranded DNA molecule of 44,500 base pairs, with a guanine-cytosine (GC) content of approximately 45%. The genome encodes 67 predicted proteins, of which 42 have assigned functions based on sequence homology, while 25 remain hypothetical.
Genomic Organization
B31’s genome is organized into distinct functional modules:
- Replication module: Genes involved in DNA synthesis, helicase activity, and primase functions.
- Structural module: Capsid, tail, and tail fiber genes.
- Packaging module: Terminase subunits and portal protein.
- Lysis module: Endolysin, holin, and spanin proteins.
- Regulatory module: Transcriptional regulators and anti-CRISPR proteins.
Key Genes
- gp23: Major capsid protein.
- gp24: Minor capsid protein.
- gp25: Tail sheath protein.
- gp36: Tail fiber protein with receptor-binding domain.
- gp40: Terminase large subunit.
- gp45: Holin protein facilitating cell lysis.
- gp50: Endolysin enzyme targeting peptidoglycan.
Life Cycle and Host Interaction
B31 follows a strictly lytic lifecycle, with no known lysogenic phase. The infection process can be summarized in the following stages:
- Attachment: Tail fibers bind to teichoic acids on the Bacillus subtilis cell wall.
- Penetration: The phage injects its DNA through the cell wall via the tail tube.
- Replication: The phage genome commandeers host replication machinery to synthesize new DNA strands.
- Assembly: Capsid and tail components are synthesized and assembled around the newly replicated genomes.
- Packaging: Terminase complexes package the phage DNA into capsids.
- Release: Holin proteins form pores in the host membrane, allowing endolysins to degrade the cell wall and release progeny virions.
Host Range Specificity
Experimental infection assays indicate that B31 can infect a subset of Bacillus subtilis strains that express specific teichoic acid modifications. Strains lacking the appropriate glycosylation patterns are resistant to B31 infection, highlighting the role of cell surface chemistry in phage susceptibility.
Applications in Molecular Biology
Due to its well‑characterized genetics and efficient lytic cycle, B31 has been adopted as a tool in several areas of biotechnology and research.
Genetic Manipulation of Bacillus subtilis
The lytic nature of B31 makes it suitable for delivering genetic cargo into Bacillus subtilis> without integrating into the host genome. Researchers have engineered B31 to carry reporter genes such as lacZ or GFP, enabling transient expression studies.
Phage Display Systems
Tail fiber proteins of B31 have been modified to display foreign peptides on the phage surface. This system is used in screening antibody libraries and identifying peptide ligands for various targets.
Biocontrol of Bacillus Contamination
B31 has potential as a biocontrol agent against pathogenic Bacillus species in industrial settings, such as food processing and dairy production. Its ability to lyse susceptible strains can reduce contamination risks.
Role in Phage Therapy Research
Phage therapy has gained renewed interest as antibiotic resistance rises. B31’s specificity for Bacillus subtilis and lack of lysogenic activity make it an attractive candidate for targeted therapeutic applications. Although Bacillus subtilis is generally considered a probiotic organism, certain strains can act as opportunistic pathogens, especially in immunocompromised individuals.
Safety Assessment
Extensive in vitro studies have confirmed that B31 does not carry genes for toxins, antibiotic resistance, or lysogenic integration. Its lytic cycle ensures that the phage is eliminated from the host once the infection cycle concludes.
In Vivo Studies
Animal models, such as murine infection systems, have demonstrated that B31 can reduce bacterial load without eliciting significant inflammatory responses. However, further research is needed to evaluate efficacy in clinical scenarios.
Research Tools and Methodologies
Several protocols have been developed for the use of B31 in laboratory settings. These include:
- Isolation and purification of phage particles via cesium chloride gradient centrifugation.
- Quantification of phage titer using plaque assays on soft agar overlays.
- Genome sequencing using Illumina or Oxford Nanopore platforms for high‑resolution genetic analysis.
- CRISPR-Cas-based editing of phage genes to study gene function.
Historical Significance and Discoveries
B31 was first reported in 1964 by Dr. A. J. Smith in a seminal paper that described the isolation of a new Bacillus phage from agricultural soil. Subsequent studies by the same group elucidated its lytic nature and host specificity. The 1978 characterization of its tail fibers by Dr. L. K. Nguyen established the importance of teichoic acid interactions in phage attachment.
Key Milestones
- 1964 – Isolation and initial characterization.
- 1972 – Determination of genome size via gel electrophoresis.
- 1981 – Identification of the holin-endolysin system.
- 1993 – Complete genomic sequencing.
- 2005 – Development of tail fiber display technology.
- 2015 – Application in phage therapy research.
Comparative Genomics
Comparative analysis of B31 with related phages such as P1, P2, and SP1 reveals both conserved and unique genetic elements. B31 shares approximately 70% sequence identity with P1 in the replication module but diverges significantly in the tail fiber genes, which accounts for its distinct host range.
Phylogenetic Analysis
Phylogenetic trees constructed using the terminase large subunit sequences place B31 within a clade of soil-derived Bacillus phages. This clade is distinct from the group of temperate Bacillus phages, reinforcing the classification of B31 as strictly lytic.
Resistance and Host Defense Mechanisms
Bacillus subtilis employs several defense strategies against phage infection, including restriction-modification systems, CRISPR-Cas adaptive immunity, and abortive infection systems. Studies have shown that B31 can evade some of these defenses by incorporating anti-CRISPR proteins encoded in its genome.
CRISPR-Cas Interference
When B31 infects a Bacillus strain with a CRISPR array targeting phage DNA, the anti-CRISPR proteins inhibit Cas9 activity, allowing successful infection. Mutagenesis of these anti-CRISPR genes reduces B31’s infectivity, confirming their role in immune evasion.
Current Research and Emerging Technologies
Recent studies have focused on the following areas:
- Engineering B31 for multiplexed gene delivery: Incorporating multiple reporter genes or CRISPR components into the phage genome.
- Structural biology of the tail fiber-receptor complex: High-resolution cryo‑EM studies aim to elucidate the molecular basis of host specificity.
- Phage–microbiome interactions: Investigating how B31 influences the Bacillus population dynamics in soil ecosystems.
- Synthetic biology applications: Using B31 as a chassis for constructing minimal phage-based gene circuits.
Potential Future Directions
Several promising avenues for future research include:
- Development of B31‑based diagnostic kits for rapid detection of Bacillus contamination.
- Engineering B31 to target multidrug-resistant Bacillus strains.
- Exploring the use of B31 in combination therapies with antibiotics to enhance bacterial clearance.
- Investigating the environmental impact of releasing engineered phages into agricultural settings.
Conservation and Distribution
B31 has been isolated from diverse ecological niches, including temperate agricultural soils, forest leaf litter, and river sediments. Its prevalence in soil environments suggests a stable ecological role in controlling Bacillus populations. However, the phage’s distribution is limited to environments where susceptible Bacillus strains are present.
See Also
For related topics, consider reviewing:
- Caudovirales – Order of tailed bacteriophages.
- Siphoviridae – Family encompassing long-tailed phages.
- Phage therapy – Use of bacteriophages to treat bacterial infections.
- CRISPR-Cas systems – Adaptive immune mechanisms in bacteria.
- Phage display – Technology for presenting peptides on phage surfaces.
No comments yet. Be the first to comment!